Clinical research of comparison of pain for intracutaneous injection of recombinant human erythropoietin in patients with chronic kidney disease at predialysis stage

Clinical research of comparison of pain for intracutaneous injection of recombinant human erythropoietin in patients with chronic kidney disease at predialysis stage - Comparison of pain for intracutaneous injection of erythropoietin in patients with chronic kidney disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001894

Enrollment

Registered

2010-01-01

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease at predialysis stage

Interventions

Recombinant human erythropoietin (epogin) Recombinant human erythropoietin (espo)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outdepartment patients with chronic kidney disease at predialysis stage receiving ricombinant human erythropoietin at a dose of 12000 IU

Exclusion criteria

Exclusion criteria: Patients with disturbance of peripheral nervous system, disturbance of sensory nervous system and hemiplegia

Design outcomes

Primary

Measure	Time frame
Pain of injection part	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026